US FDA Supply Chain Guidance Includes More Stakeholders, More Risks Than CARES Act

Draft guidance on redundancy risk management plans layers risk-based expectations over new statutory requirements to plan more resilient supply chains for critical drugs.

medicine stocks
fda recommends more planning to keep shelves stocked • Source: Shutterstock

The US FDA has drafted guidance on congressionally mandated supply chain “redundancy risk management plans” that says who the agency expects to develop the plans, what it expects the plans to contain, what drug products they should cover, and how they should be developed.

The FDA recommends more stakeholders develop the plans than the March 2020 Coronavirus Aid, Relief and Economic Security Act requires,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Distribution/Supply Chain

Akash test for clone

 
• By 

Test article to check the clone issue

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

French Fine 11 Firms For Failure To Meet Stock Obligations

 
• By 

A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

More from Compliance

HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments

 

Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

 

The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.